secwatch.observer — SEC 8-K summary
======================================

Issuer:     FATE THERAPEUTICS INC (FATE)
CIK:        0001434316
Form:       8-K
Filed at:   2025-10-14T23:59:59+00:00
Accession:  0001193125-25-238989
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fate Therapeutics appoints Kamal Adawi as CFO, board resignations reduce size from 10 to 8
--------------------------------------------------------------------------------

- Kamal Adawi appointed CFO effective Oct 20, 2025; base salary $495k, target bonus 40%.
- Adawi receives 375k stock option and 75k RSUs as inducement equity grants, vesting over 4 years.
- Board members John Mendlein and Neelufar Mozaffarian resigned voluntarily effective Oct 13, 2025.
- Board size decreased from 10 to 8 directors following resignations.
- CFO role focused on supporting registrational path for FT819 in SLE and pipeline progress.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434316/000119312525238989/0001193125-25-238989-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434316/000119312525238989/fate-20251010.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-238989

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer